Adaptive Biotechnologies Corporation (ADPT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer
Adaptive Biotechnologies Corporation (ADPT) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
ADPT Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING
Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ADPT)
No recent open-market Form 4 cluster sales or emergency dumps flagged on ADPT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring ADPT)
- ✓Live walkthrough of ADPT's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
ADPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +54.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ADPT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ADPT. Explore sector supply chains on /butterfly.
ADPT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDAre ADPT insiders and hedge funds buying or selling?
Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ADPT leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.